Cellular Oncology (Jan 2009)

Presence of a High Amount of Stroma and Downregulation of SMAD4 Predict for Worse Survival for Stage I–II Colon Cancer Patients

  • Wilma E. Mesker,
  • Gerrit-Jan Liefers,
  • Jan M. C. Junggeburt,
  • Gabi W. van Pelt,
  • Paola Alberici,
  • Peter J. K. Kuppen,
  • Noel F. Miranda,
  • Karin A. M. van Leeuwen,
  • Hans Morreau,
  • Karoly Szuhai,
  • Rob A. E. M. Tollenaar,
  • Hans J. Tanke

DOI
https://doi.org/10.3233/CLO-2009-0478
Journal volume & issue
Vol. 31, no. 3
pp. 169 – 178

Abstract

Read online

Background: For stage I–II colon cancer a significant number (5–25%) of patients has recurrent disease within 5 years. There is need to identify these high-risk patients as they might benefit from additional treatment.